The $50M ASR is a clear signal of management's view that the stock is undervalued and will mechanically reduce share count by ~4.8%, providing a modest EPS tailwind. Traders should watch for the final settlement details in Q4 2026 and any subsequent updates on the remaining $100M authorization. The stock's recent underperformance (historical T+20 avg -5.31% on prior calls) suggests skepticism, but this buyback is a concrete capital return action that may support the stock near term.
Price Chart
Executive Summary
Collegium Pharmaceutical announced an accelerated share repurchase (ASR) agreement with Jefferies LLC to repurchase $50 million of its common stock, as part of a previously authorized $150 million buyback program. The company will receive an initial delivery of ~1.56 million shares (80% of expected total) based on the $25.70 closing price, with final settlement by Q4 2026. This signals management's confidence in the company's valuation and capital allocation, though it does not provide new information on underlying business fundamentals.
Key Facts
- Collegium entered an accelerated share repurchase (ASR) agreement with Jefferies LLC to repurchase $50 million of its common stock.
- The ASR is part of a $150 million share repurchase program authorized by the Board in July 2025.
- Initial delivery of 1,556,420 shares based on the $25.70 closing price on August 12, 2026, representing ~80% of expected total repurchase.
- Final settlement expected no later than Q4 2026; as of June 30, 2026, Collegium had ~32.5 million shares outstanding.
Financial Impact
$50 million accelerated share repurchase, representing ~4.8% of shares outstanding at the initial delivery price (1.56M shares / 32.5M shares outstanding)
Risk Factors
- The buyback does not address underlying business fundamentals or revenue growth trajectory.
- If the stock price declines further, the ASR locks in repurchases at a higher average cost than if the company had waited.
- Historical performance on COLL reports shows a 40% win rate at T+20, indicating the stock has been difficult to call directionally.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-095464 |
| Document: 0001104659-26-095464-index-headers.html | 0001104659-26-095464 |
| Document: 0001104659-26-095464-index.html | 0001104659-26-095464 |
| Document: 0001104659-26-095464.txt | 0001104659-26-095464 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 19, 2026 6w ago | Court Ruling | $28.74 $22.38 | ▼ −22.13% | ▼ −20.18% | $22.08 (−23.19%) |
Aug 13, 2026 7w ago | 8-K | $28.15 $22.75 | ▼ −19.18% | ▼ −17.44% | $22.08 (−21.58%) |
Aug 6, 2026 8w ago | 8-K | $29.11 $23.70 | ▼ −18.58% | ▼ −19.18% | $22.08 (−24.17%) |
May 15, 2026 19w ago | Insider Cluster | $33.65 $34.65 | ▲ +2.97% | ▲ +1.39% | $22.08 (−34.40%) |
May 12, 2026 20w ago | Press Release | $35.69 $34.80 | ▼ −2.49% | ▼ −0.77% | $22.08 (−38.15%) |
May 11, 2026 20w ago | 144 | $35.81 $34.40 | ▼ −3.94% | ▼ −3.63% | $22.08 (−38.36%) |
Apr 23, 2026 23w ago | Press Release | $32.28 $34.22 | ▲ +6.01% | ▲ +1.38% | $22.08 (−31.61%) |
Apr 7, 2026 25w ago | 8-K | $33.43 $35.32 | ▲ +5.65% | ▼ −2.89% | $22.08 (−33.97%) |
Mar 19, 2026 28w ago | Press Release | $36.30 $34.41 | ▼ −5.21% | ▼ −12.83% | $22.08 (−39.19%) |
Mar 3, 2026 30w ago | Press Release | $39.99 $33.07 | ▼ −17.30% | ▼ −12.90% | $22.08 (−44.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access